{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T10:12:10Z","timestamp":1777975930519,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Glaucoma"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ogla.2022.02.009","type":"journal-article","created":{"date-parts":[[2022,2,20]],"date-time":"2022-02-20T09:49:51Z","timestamp":1645350591000},"page":"516-524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Topical 0.1% Nepafenac versus 0.09% Bromfenac Eye Drops for Inflammation after Laser Peripheral Iridotomy"],"prefix":"10.1016","volume":"5","author":[{"given":"Lavanya G.","family":"Shankar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annamalai","family":"Odayappan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aakriti Garg","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishwaraj C.","family":"Ramaswamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkatesh","family":"Rengaraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9796-6981","authenticated-orcid":false,"given":"Kavitha","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ogla.2022.02.009_bib1","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","article-title":"Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the right to sight: an analysis for the Global Burden of Disease Study","volume":"9","year":"2021","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.ogla.2022.02.009_bib2","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/S0161-6420(03)00564-5","article-title":"Glaucoma in a rural population of southern India: the Aravind comprehensive eye survey","volume":"110","author":"Ramakrishnan","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2022.02.009_bib3","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1136\/bjo.85.11.1277","article-title":"Glaucoma in China: how big is the problem?","volume":"85","author":"Foster","year":"2001","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ogla.2022.02.009_bib4","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1136\/bjo.85.9.1019","article-title":"Who needs an iridotomy?","volume":"85","author":"Friedman","year":"2001","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ogla.2022.02.009_bib5","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.ophtha.2015.04.015","article-title":"Use of various glaucoma surgeries and procedures in Medicare beneficiaries from 1994 to 2012","volume":"122","author":"Arora","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2022.02.009_bib6","series-title":"Becker-Shaffer\u2019s diagnosis and therapy of the glaucomas","first-page":"447","article-title":"Laser treatment for internal flow block","author":"Berlin","year":"2009"},{"key":"10.1016\/j.ogla.2022.02.009_bib7","first-page":"198","article-title":"Intra ocular pressure response to topical corticosteroids","volume":"4","author":"Becker","year":"1965","journal-title":"Invest Ophthalmol"},{"key":"10.1016\/j.ogla.2022.02.009_bib8","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1136\/bjophthalmol-2014-306557","article-title":"Steroid-induced glaucoma and childhood blindness","volume":"99","author":"Gupta","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ogla.2022.02.009_bib9","first-page":"187","article-title":"Statistical attributes of the steroid hypertensive response in the clinically normal eye. I. The demonstration of three levels of response","volume":"4","author":"Armaly","year":"1965","journal-title":"Invest Ophthalmol"},{"key":"10.1016\/j.ogla.2022.02.009_bib10","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1136\/bjo.86.12.1380","article-title":"Effects of dexamethasone, diclofenac, or placebo on the inflammatory response after cataract surgery","volume":"86","author":"Laurell","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ogla.2022.02.009_bib11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/bjo.81.4.299","article-title":"Comparison of the efficacy of diclofenac and betamethasone following strabismus surgery","volume":"81","author":"Wright","year":"1997","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ogla.2022.02.009_bib12","doi-asserted-by":"crossref","first-page":"606","DOI":"10.4103\/0301-4738.129781","article-title":"Topical nepafenac 0.1% alone versus prednisolone acetate 1% as postoperative anti-inflammatory agents in small gauge vitrectomy","volume":"62","author":"Nagpal","year":"2014","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.ogla.2022.02.009_bib13","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.ophtha.2019.05.032","article-title":"SALT trial: steroids after laser trabeculoplasty: impact of short-term anti-inflammatory treatment on selective laser trabeculoplasty efficacy","volume":"126","author":"Groth","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2022.02.009_bib14","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ogla.2020.02.006","article-title":"Safety and efficacy of 0.1% nepafenac versus 1% prednisolone acetate eye drops after laser peripheral iridotomy: a prospective, randomized trial","volume":"3","author":"Gayam","year":"2020","journal-title":"Ophthalmol Glaucoma"},{"key":"10.1016\/j.ogla.2022.02.009_bib15","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1023\/A:1007001131987","article-title":"Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In\u00a0vitro bioactivation and permeation of external ocular barriers","volume":"24","author":"Ke","year":"2000","journal-title":"Inflammation"},{"key":"10.1016\/j.ogla.2022.02.009_bib16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.iio.0000212134.83513.11","article-title":"Global experience with xibrom (Bromfenac ophthalmic solution) 0.09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug","volume":"46","author":"Donnenfeld","year":"2006","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.ogla.2022.02.009_bib17","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/bjo.86.2.238","article-title":"The definition and classification of glaucoma in prevalence surveys","volume":"86","author":"Foster","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ogla.2022.02.009_bib18","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1001\/archopht.116.7.861","article-title":"The Glaucoma Symptom Scale. A brief index of glaucoma-specific symptoms","author":"Lee","year":"1998","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ogla.2022.02.009_bib19","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ogla.2022.02.009_bib20","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/0002-9394(70)92463-3","article-title":"Uveitis in association with topically administered corticosteroid","volume":"70","author":"Krupin","year":"1970","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ogla.2022.02.009_bib21","series-title":"Cataract Surgery","first-page":"221","article-title":"Complications associated with cataract surgery","author":"Ismail","year":"2013"},{"key":"10.1016\/j.ogla.2022.02.009_bib22","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1089\/jop.2008.0023","article-title":"Nepafenac dosing frequency for ocular pain and inflammation associated with cataract surgery","volume":"24","author":"Maxwell","year":"2008","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ogla.2022.02.009_bib23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jcrs.2006.08.043","article-title":"Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery","volume":"33","author":"Lane","year":"2007","journal-title":"J\u00a0Cataract Refract Surg"},{"key":"10.1016\/j.ogla.2022.02.009_bib24","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/IAE.0b013e31821e2057","article-title":"Role of topical nepafenac in prevention and treatment of macular edema after vitreoretinal surgery","volume":"32","author":"Naithani","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.ogla.2022.02.009_bib25","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1517\/14656560903188425","article-title":"Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent","volume":"10","author":"Jones","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ogla.2022.02.009_bib26","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1089\/jop.2007.0040","article-title":"The systemic safety of bromfenac ophthalmic solution 0.09%","volume":"23","author":"Stewart","year":"2007","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ogla.2022.02.009_bib27","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00417-017-3599-8","article-title":"The comparative efficacy and safety of topical non-steroidal anti-inflammatory drugs for the treatment of anterior chamber inflammation after cataract surgery: a systematic review and network meta-analysis","volume":"255","author":"Duan","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ogla.2022.02.009_bib28","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1007\/BF02877774","article-title":"Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK)","volume":"24","author":"Durrie","year":"2007","journal-title":"Adv Ther"},{"key":"10.1016\/j.ogla.2022.02.009_bib29","first-page":"1210","article-title":"Comparative study of the efficacy and safety of bromfenac, nepafenac and diclofenac sodium for the prevention of cystoid macular edema after phacoemulsification","volume":"11","author":"Chinchurreta Capote","year":"2018","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.ogla.2022.02.009_bib30","first-page":"527","article-title":"Analgesic and anti-inflammatory effectiveness of nepafenac 0.1% for cataract surgery","volume":"1","author":"Nardi","year":"2007","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ogla.2022.02.009_bib31","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.ophtha.2006.12.029","article-title":"Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation","volume":"114","author":"Donnenfeld","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2022.02.009_bib32","first-page":"1451","article-title":"Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK","volume":"5","author":"Wang","year":"2011","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ogla.2022.02.009_bib33","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ajo.2013.12.015","article-title":"Effect of nepafenac eye drops on intraocular pressure: a randomized prospective study","volume":"157","author":"Dave","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ogla.2022.02.009_bib34","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1097\/IAE.0b013e31817e7ead","article-title":"Topical nepafenac as an alternate treatment for cystoid macular edema in steroid responsive patients","volume":"28","author":"Warren","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.ogla.2022.02.009_bib35","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1097\/IJG.0000000000000293","article-title":"Effect of laser peripheral iridotomy on anterior chamber angle anatomy in primary angle closure spectrum Eyes","volume":"25","author":"Kansara","year":"2016","journal-title":"J\u00a0Glaucoma"},{"key":"10.1016\/j.ogla.2022.02.009_bib36","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4103\/0301-4738.62655","article-title":"The Chennai glaucoma study: prevalence and risk factors for glaucoma in cataract operated eyes in urban Chennai","volume":"58","author":"George","year":"2010","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.ogla.2022.02.009_bib37","first-page":"81","article-title":"Prevalence of primary glaucoma in an urban South Indian population","volume":"46","author":"Jacob","year":"1998","journal-title":"Indian J Ophthalmol"}],"container-title":["Ophthalmology Glaucoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589419622000278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589419622000278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:53:53Z","timestamp":1762887233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589419622000278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2589419622000278"],"URL":"https:\/\/doi.org\/10.1016\/j.ogla.2022.02.009","relation":{},"ISSN":["2589-4196"],"issn-type":[{"value":"2589-4196","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical 0.1% Nepafenac versus 0.09% Bromfenac Eye Drops for Inflammation after Laser Peripheral Iridotomy","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Glaucoma","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ogla.2022.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}